pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 17·1 min read
save

NIH Diversity Programs Found to Double Undergraduate PhD Odds in 20-Year Study

Jun 17, 2026·read at STAT ↗Neutral

A 20‑year study published in Science Advances reports that two NIH‑funded diversity initiatives, the Research Initiative for Scientific Enhancement (RISE) and Minority Access to Research Careers (MARC), doubled the likelihood that an undergraduate student would go on to earn a Ph.D.

The analysis covered a large cohort of students and compared outcomes for participants in the programs with those who did not receive the support, finding a clear advantage for the former group.

Both RISE and MARC lost their federal funding last year after the Trump administration ended the initiatives, and the study’s own funding was also terminated.

Researchers say the results highlight the value of mentoring and targeted support for underrepresented students, especially as the political environment becomes less favorable to such programs.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “NIH diversity programs doubled undergraduates’ odds of getting a Ph.D., 20-year study finds”

read at STAT ↗
1,177 words · retrieved Jun 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PATH2NOVONational Institutes of Health
topics
AdComApprovalVaccine

related stories

  • 21h agoArsenalBio lays off 99 employees, leaving ‘core team’ to advance in vivo strategyBioSpace
  • Aug 24Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand aloneBioSpace
  • Aug 14Capricor soars on potential FDA review extension, filing amendmentsBioSpace
  • Aug 6Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he wasSTAT
  • Aug 6FDA approves Moderna’s mRNA flu vaccineBioPharma Dive